FDA/CDC

FDA Approves Pfizer’s Hympavzi for Hemophilia A, B


 

The Food and Drug Administration (FDA) has approved Hympavzi (marstacimab, Pfizer) as routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients 12 years or older who have hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors.

The once-weekly subcutaneous injection targets an anticoagulation protein called tissue factor pathway inhibitor (TFPI). Reducing TFPI’s amount and activity in the blood subsequently increases the amount of thrombin, a pro-clotting enzyme, in circulation.

“Today’s approval of Hympavzi provides patients with hemophilia a new treatment option that is the first of its kind to work by targeting a protein in the blood clotting process,” Ann Farrell, MD, director of FDA’s Division of Non-Malignant Hematology, said in an agency press release.

Hympavzi is the first non-factor, once-weekly treatment for hemophilia B in the United States. The subcutaneous injection emicizumab (Hemlibra, Genentech), which works by a different mechanism, is already on the market for hemophilia A.

The current approval was based on the open-label BASIS trial in 116 men and boys with either severe hemophilia A or B without factor inhibitors.

During the trial’s first 6 months, patients received standard treatment with clotting factor replacement either on-demand (33 patients) or prophylactically (83 patients). Patients were then switched to Hympavzi prophylaxis for a year.

Among patients receiving on-demand standard treatment during the first 6 months, the annualized bleeding rate was 38 episodes. That rate fell to 3.2 episodes during treatment with Hympavzi.

Among patients receiving prophylactic standard treatment during the first 6 months, the estimated annualized bleeding rate was 7.85 episodes, which then fell to 5.08 during the year of Hympavzi prophylaxis, FDA said.

Injection-site reactions, headaches, and itching were the most common side effects with marstacimab, occurring in 3% or more of patients. Labeling warns of the potential for circulating blood clots, hypersensitivity, and embryofetal toxicity. Marstacimab is supplied in prefilled syringes.

Marstacimab is Pfizer’s second hemophilia approval in 2024. FDA approved the company’s hemophilia B gene therapy fidanacogene elaparvovec (Beqvez) in April.

Pfizer noted in a press release that results for another arm of the BASIS trial in patients with clotting factor inhibitors are expected in 2025.

A version of this article first appeared on Medscape.com.

Recommended Reading

EU Backs First Oral Monotherapy for Adults With PNH
MDedge Hematology and Oncology
FDA OKs Danicopan Add-On for Extravascular Hemolysis in Adults With PNH
MDedge Hematology and Oncology
FDA Approves Second Gene Therapy for Hemophilia B
MDedge Hematology and Oncology
SCD: Delaying Transition to Adult Care Poses Risks
MDedge Hematology and Oncology
Beta Thalassemia: Pricey Gene Therapy Hits The Mark
MDedge Hematology and Oncology
Hemophilia: Marstacimab Sustains Long-Term Bleeding Reduction
MDedge Hematology and Oncology
Hemophilia: Novel Tx Also Cuts Bleeding in Kids
MDedge Hematology and Oncology
Two Soliris Biosimilars Approved for PNH in the US
MDedge Hematology and Oncology
No Matched Sibling Donor? Sickle Cell Experts Debate Next-Best Option
MDedge Hematology and Oncology
Pfizer’s Withdrawal of SCD Drug Raises Questions
MDedge Hematology and Oncology